Oxaliplatin Injection

Listing ID #1314553

Get Latest Price

Supply Type Manufacturer, Exporter, Supplier
Preferred Buyer Location All over the world

We are a reputed Supplier and Exporter of Oxaliplatin Injection. Oxaliplatin Injection is used for the treatment of colorectal cancer. We provide Oxaliplatin Injection in well-sealed packaging and assure quality of the product as well. We offer Oxaliplatin Injection at highly competitive prices.

View More Details

Send Enquiry

Product Details

Details

Generic Name	Oxaliplatin
Brand Name	Megaplat Injection
Strength Available	50 MG. and 100 MG.
Packing	1 Vial
Name of Company	Alkem Laboratories Ltd.
Classification	Platinum analog
Mechanism of Action	Third-generation platinum compound. Cell cycle-nonspecific with activity in all phases of the cell cycle. Covalently binds to DNA with preferential binding to the N-7 position of guanine and adenine. Reacts with two different sites on DNA to produce cross-links, either intrastrand (> 90%) or interstrand « 5%). Formation of DNA adducts results in inhibition of DNA synthesis and function as well as inhibition of transcription. DNA mismatch repair enzymes are unable to recognize Qxaliplatin-DNA adducts in contrast with other platinum-DNA adducts as a result of their bulkier size. Binding to nuclear and cytoplasmic proteins may result in additional cytotoxic effects.
Mechanism of Resistance	Decreased drug accumulation due to alterations in cellular transport. Increased inactivation by thiol-containing proteins such as glutathione and glutathionerelated enzymes. Increased DNA repair enzyme activity (e.g., ERCC-1). Non-cross-resistant to cisplatin and carboplatin in tumor cells that are deficient in mismatch repair (MMR) enzymes (e.g., hMHL 1, hMSH2).
Absorption	Not orally bioavailable.
Distribution	Widely distributed to all tissues with a 50-fold higher volume of distribution than cisplatin. About 40% of drug is sequestered in red blood cells within 2-5 hours of infusion. Extensively binds to plasma proteins in a time-dependent manner (up to 98%).
Metabolism	Oxaliplatin undergoes extensive nonenzymatic conversion to its active cytotoxic species. As observed with cisplatin, oxaliplatin undergoes aquation reaction in the presence of low concentrations of chloride. The major species are monochloro-DACH, dichloro-DACH, and mono-diaquo-DACH platinum. Renal excretion accounts for> 50% of oxaliplatin clearance. More than 20 different metabolites have been identified in the urine. Only 2% of drug is excreted in feces. Prolonged terminal half-life of up to 240 hours.
Indications & Usage	Metastatic colorectal cancer - FDA approved as second-line therapy in combination with 5-FU/LV (FOLFOX4) in patients whose disease has recurred or progressed during or within 6 months of completion of first-/ine therapy with the combination of bolus 5-FU/LV and irinotecan (IFL Saltz regimen). Metastatic colorectal cancer - First-line therapy in combination with 5-FU/LV (FOLFOX4). Early-stage colon cancer - Adjuvant therapy in combination with 5-FU/LV (FOLFOX4) in patients with stage III colon cancer and in those with high-risk stage II disease.
Dosage Range	Recommended dose is 130 mg/m2 IV over 6 hours, on an every-3-week schedule. Can also give 85 mg/m2 IV over 2 hours, on an every-2-week schedule.
Drung Preparation	Available in SO and 100 mg vials for IV use. Dilute with 10-40 mL of either sterile water or 5% dextrose solution. Further dilute in a soiution of 250 or SOO mL of 5% dextrose solution. Do not administer drug undiluted. NEVER use 0.9% sodium chloride or saline-containing solutions. Reconstituted solution is stable for 24 hours at room temperature.
Drung Interaction	None known.
Special Considerations	Use with caution in patients with abnormal renal function. Baseline creatinine clearance should be obtained, and renal status must be closely monitored during treatment. Oxaliplatin should not be administered with basic solutions (e.g., solutions containing 5-FU) as it may be partially degraded. Careful neurologic evaluation should be performed before starting therapy and at the beginning of each cycle as the dose-limiting toxicity of oxaliplatin is neurotoxicity. Caution patients to avoid exposure to cold, which can trigger and/or worsen neurotoxicity.
Toxicity	Neurotoxicity is dose-limiting. Characterized mainly by a peripheral sensory neuropathy with distal paresthesias, often triggered or exacerbated by cold. Acute dysesthesias in the upper extremities and laryngopharyngeal region with episodes of difficulty breathing or swallowing, usually observed within hours or 1-3 days after therapy. Risk increases upon exposure to cold and usually is spontaneously reversible. A 15% and> 50% risk of impairment in propioception and neurosensory function at cumulative doses of 850 and 1,200 mg/m2, respectively. In contrast with cisplatin-induced neurotoxicity, oxaliplatininduced neuropathy is frequently reversible, usually within 3-4 months of discontinuation of oxaliplatin. Nausea and vomiting. Occurs in 65% of patients treated with single-agent oxaliplatin and in 90% of patients treated with the combination of 5-FU/LV and oxaliplatin. Well-controlled with antiemetic therapy. Diarrhea. Observed in 30% of patients treated with monotherapy but in 80%-90% of patients treated with combination chemotherapy. Myelosuppression. Relatively mild with thrombocytopenia and anemia more common than neutropenia. Allergic reactions with facial flushing, rash, urticaria, and less frequently, bronchospasm and hypotension. Renal toxicity is uncommon with only 5% of patients experiencing grade 1 toxicity. Ototoxicity. Occurs rarely in contrast to cisplatin.